136470-78-5 | Abacavir

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
50mg	98%	in stock	$8.00	$6.00
1g	98%(HPLC)	in stock	$24.00	$17.00
5g	98%(HPLC)	in stock	$68.00	$48.00
25g	98%	in stock	$143.00	$101.00

Description

• Catalog Number: AA48916
• Chemical Name: Abacavir
• CAS Number: 136470-78-5
• Molecular Formula: C14H18N6O
• Molecular Weight: 286.3323
• MDL Number: MFCD00903850
• SMILES: OC[C@@H]1C=C[C@@H](C1)n1cnc2c1nc(N)nc2NC1CC1

Computed Properties

• Complexity: 414
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 4
• XLogP3: 0.9

Literature

• An Animal Model of Abacavir-Induced HLA-Mediated Liver Injury.

  Toxicological sciences : an official journal of the Society of Toxicology 20180401

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.

  eLife 20170101

• Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.

  Bioorganic & medicinal chemistry letters 20150815

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20150501

• Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission.

  PLoS pathogens 20140201

• In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

  Antimicrobial agents and chemotherapy 20131101

• T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms.

  Chemical research in toxicology 20130520

• Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.

  Antimicrobial agents and chemotherapy 20130301

• N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo.

  British journal of pharmacology 20121101

• HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients.

  European journal of gastroenterology & hepatology 20121101

• A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20121101

• Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA.

  Allergy 20121101

• A case of adverse drug reaction induced by dispensing error.

  Journal of forensic and legal medicine 20121101

• A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20121001

• Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

  AIDS research and human retroviruses 20121001

• Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.

  Journal of pharmacy practice 20121001

• Antiretroviral neurotoxicity.

  Journal of neurovirology 20121001

• Trade deal to curb generic-drug use.

  Nature 20120906

• Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.

  HIV medicine 20120901

• Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity.

  Genetic testing and molecular biomarkers 20120901

• Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children.

  British journal of clinical pharmacology 20120801

• Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.

  HIV medicine 20120801

• Tailoring drug therapy based on genotype.

  Journal of pharmacy practice 20120801

• HLA and pharmacogenetics of drug hypersensitivity.

  Pharmacogenomics 20120801

• Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.

  AIDS (London, England) 20120717

• Avidity determines T-cell reactivity in abacavir hypersensitivity.

  European journal of immunology 20120701

• Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children.

  Current opinion in HIV and AIDS 20120701

• Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.

  Journal of acquired immune deficiency syndromes (1999) 20120701

• Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

  Nature 20120628

• Pharmacology: A false sense of non-self.

  Nature 20120627

• Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.

  Proceedings of the National Academy of Sciences of the United States of America 20120619

• Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

  AIDS (London, England) 20120601

• Detection of abacavir hypersensitivity by ELISpot method.

  Inflammation & allergy drug targets 20120601

• Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120601

• Disseminated penicilliosis in a Korean human immunodeficiency virus infected patient from Laos.

  Journal of Korean medical science 20120601

• Tools for eradicating HIV in the brain: prodrug dimeric inhibitors of P-gp.

  Therapeutic delivery 20120601

• Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

  Gastroenterology 20120501

• Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.

  PLoS medicine 20120501

• Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

  British journal of clinical pharmacology 20120401

• [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].

  Enfermedades infecciosas y microbiologia clinica 20120401

• HLA alleles and drug hypersensitivity reactions.

  International journal of immunogenetics 20120401

• Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.

  HIV medicine 20120401

• How informative is a negative finding in a small pharmacogenetic study?

  The pharmacogenomics journal 20120401

• Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

  Clinical pharmacology and therapeutics 20120401

• HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures.

  Current HIV research 20120401

• HIV exposure through contact with body fluids.

  Prescrire international 20120401

• A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315

• Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.

  AIDS (London, England) 20120313

• Enantioselective synthesis of the carbocyclic nucleoside (-)-abacavir.

  Organic & biomolecular chemistry 20120307

• Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.

  AIDS research and human retroviruses 20120301

• Endothelial and platelet function alterations in HIV-infected patients.

  Thrombosis research 20120301

• Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers.

  Sexually transmitted infections 20120301

• Exploring the complexity of the HIV-1 fitness landscape.

  PLoS genetics 20120301

• Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies.

  International journal of STD & AIDS 20120301

• Pathogenesis and treatment of human immunodeficiency virus lipodystrophy.

  Indian journal of endocrinology and metabolism 20120301

• Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.

  Journal of the American Chemical Society 20120215

• The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.

  Brain research 20120203

• Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

  International journal of epidemiology 20120201

• Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

  The Lancet. Infectious diseases 20120201

• Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

  Current infectious disease reports 20120201

• LINE-1 retrotransposon copies are amplified during murine early embryo development.

  Molecular reproduction and development 20120201

• Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

  Clinical pharmacology and therapeutics 20120201

• Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.

  Human immunology 20120201

• Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population.

  Pharmacogenomics 20120201

• In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity.

  Pharmacogenomics 20120201

• The perils of relying on anti-hepatitis B total core antibody in screening individuals infected with HIV.

  International journal of STD & AIDS 20120201

• [Coinfection with HIV and HCV: abacavir and ribavirine, why not?].

  Revista clinica espanola 20120101

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex.

  Annual review of pharmacology and toxicology 20120101

• Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.

  AIDS patient care and STDs 20120101

• The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines.

  Experimental diabetes research 20120101

• Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.

  PloS one 20120101

• Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.

  PloS one 20120101

• Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

  Antiviral therapy 20120101

• Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

  BMC infectious diseases 20120101

• A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence.

  Patient preference and adherence 20120101

• Erythrocyte inosine triphosphatase activity is decreased in HIV-seropositive individuals.

  PloS one 20120101

• Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.

  Antiviral therapy 20120101

• Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.

  Antiviral therapy 20120101

• Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy.

  Malaria journal 20120101

• Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

  BMC infectious diseases 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.

  Antiviral therapy 20120101

• Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

  PloS one 20120101

• Spillover adherence effects of fixed-dose combination HIV therapy.

  Patient preference and adherence 20120101

• Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.

  Journal of the International AIDS Society 20120101

• Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.

  Substance abuse treatment, prevention, and policy 20120101

• Hepatitis B vaccine antibody response and the risk of clinical AIDS or death.

  PloS one 20120101

• Urgent liver transplantation for nevirapine-induced acute liver failure: report of a case and review of the literature.

  Annals of transplantation 20120101

• Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.

  PloS one 20120101

• HIV RNA suppression and immune restoration: can we do better?

  Clinical & developmental immunology 20120101

• HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

  PloS one 20120101

• Novel therapeutic strategies targeting HIV integrase.

  BMC medicine 20120101

• HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

  International journal of hepatology 20120101

• Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen.

  International journal of immunopathology and pharmacology 20120101

• Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a man with AIDS.

  International journal of general medicine 20120101

• Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases.

  Malaria journal 20120101

• Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment.

  Clinical & developmental immunology 20120101

• Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa.

  PloS one 20120101

• Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

  PloS one 20120101

• Genetics and the potential for predictive tests in adverse drug reactions.

  Chemical immunology and allergy 20120101

• Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.

  PloS one 20120101

• The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.

  Mediators of inflammation 20120101

• Human immunodeficiency virus and leprosy coinfection: challenges in resource-limited setups.

  Case reports in medicine 20120101

• Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism.

  PloS one 20120101

• Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.

  Advances in virology 20120101

• Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome.

  PloS one 20120101

• Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.

  PloS one 20120101

• Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia.

  AIDS research and treatment 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women.

  Journal of the International AIDS Society 20120101

• Chapter 30: Drug allergy.

  Allergy and asthma proceedings 20120101

• The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.

  Antiviral therapy 20120101

• Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

  Antiviral therapy 20120101

• Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity.

  Chemical research in toxicology 20111219

• Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.

  The Journal of infectious diseases 20111215

• Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.

  Journal of acquired immune deficiency syndromes (1999) 20111201

• Risk of cataract surgery in HIV-infected individuals: a Danish Nationwide Population-based cohort study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111201

• Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.

  Virologica Sinica 20111201

• Drug resistance in HIV-1.

  Current opinion in virology 20111201

• Malaria therapy in HIV: drug interactions between nevirapine and quinine.

  International journal of STD & AIDS 20111201

• Herpes zoster as a sign of AIDS and nonadherence to antiretroviral therapy: a case report.

  Clinics (Sao Paulo, Brazil) 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Genetic correlates influencing immunopathogenesis of HIV infection.

  The Indian journal of medical research 20111201

• Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

  The Indian journal of medical research 20111201

• Human immunodeficiency virus & cardiovascular risk.

  The Indian journal of medical research 20111201

• Paediatric HIV--trends & challenges.

  The Indian journal of medical research 20111201

• Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.

  AIDS (London, England) 20111128

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

  Clinical drug investigation 20111101

• Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.

  AIDS (London, England) 20111023

• Abacavir and myocardial infarctions: the benefit of doubt?

  AIDS (London, England) 20111023

• Optimizing initial therapy for HIV infection.

  The Journal of infectious diseases 20111015

• Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

  The Journal of infectious diseases 20111015

• Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.

  The Journal of infectious diseases 20111015

• A new approach to safely type for HLA the HIV infected people eligible to abacavir therapy: saliva or buccal swab as reliable DNA sources.

  Clinica chimica acta; international journal of clinical chemistry 20111009

• Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20111001

• Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.

  AIDS patient care and STDs 20111001

• [Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].

  Deutsche medizinische Wochenschrift (1946) 20111001

• A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.

  The Journal of infectious diseases 20110915

• Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?

  British journal of clinical pharmacology 20110901

• Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

  Journal of acquired immune deficiency syndromes (1999) 20110901

• Abacavir and lamivudine for the treatment of human immunodeficiency virus.

  Expert opinion on pharmacotherapy 20110901

• [Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].

  Medecine et maladies infectieuses 20110901

• Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders.

  PLoS pathogens 20110901

• Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti.

  PLoS medicine 20110901

• Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic.

  Central European journal of public health 20110901

• Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N(6)- or O(6)-substituted purine or 2-aminopurine nucleoside monophosphates.

  Journal of medicinal chemistry 20110825

• Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study.

  AIDS (London, England) 20110824

• DRESS syndrome associated with raltegravir.

  Dermatology online journal 20110815

• Medication-based urolithiasis and atazanavir.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20110809

• Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

  The Pediatric infectious disease journal 20110801

• Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.

  The Journal of antimicrobial chemotherapy 20110801

• Treatment of Asian flush with abacavir.

  Medical hypotheses 20110801

• Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy.

  AIDS patient care and STDs 20110801

• Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.

  Journal of acquired immune deficiency syndromes (1999) 20110801

• Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.

  Clinics (Sao Paulo, Brazil) 20110801

• Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa.

  Journal of health, population, and nutrition 20110801

• Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications.

  Clinical epigenetics 20110801

• Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

  Lancet (London, England) 20110716

• Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.

  Clinica chimica acta; international journal of clinical chemistry 20110715

• Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.

  Journal of acquired immune deficiency syndromes (1999) 20110701

• Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity.

  Tissue antigens 20110701

• Cardiovascular disease in HIV infection.

  Current opinion in HIV and AIDS 20110701

• Risk factors of chronic kidney disease in HIV-infected patients.

  Clinical journal of the American Society of Nephrology : CJASN 20110701

• Bioinformatics challenges for personalized medicine.

  Bioinformatics (Oxford, England) 20110701

• Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110701

• HIV and Cardiovascular Disease.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110701

• Personalized medicine: new genomics, old lessons.

  Human genetics 20110701

• Injury secondary to antiretroviral agents: retrospective analysis of a regional poison center database.

  The western journal of emergency medicine 20110701

• Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations.

  Nature genetics 20110626

• Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

  AIDS (London, England) 20110619

• Acetoxy Meldrum's acid: a versatile acyl anion equivalent in the Pd-catalyzed asymmetric allylic alkylation.

  Organic letters 20110617

• Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

  The Journal of infectious diseases 20110615

• Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.

  The Pediatric infectious disease journal 20110601

• The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

  Antimicrobial agents and chemotherapy 20110601

• Can fomepizole be substituted by abacavir in the treatment of methanol poisoning?

  Journal of medical toxicology : official journal of the American College of Medical Toxicology 20110601

• Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.

  Pharmacogenomics 20110601

• Major HIV resistance mutations in untreated Romanian patients.

  Journal of medicine and life 20110515

• Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

  AIDS research and human retroviruses 20110501

• Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor.

  Journal of fluorescence 20110501

• From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.

  Expert opinion on drug safety 20110501

• Hypersensitivity reactions to HIV therapy.

  British journal of clinical pharmacology 20110501

• Epidemiology and risk factors for drug allergy.

  British journal of clinical pharmacology 20110501

• Delayed drug hypersensitivity: models of T-cell stimulation.

  British journal of clinical pharmacology 20110501

• CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope.

  PLoS pathogens 20110501

• FDA notifications. Abacavir sulfate tablets tentatively approved.

  AIDS alert 20110501

• FDA notifications. Ongoing safety review of abacavir, possible MI risk.

  AIDS alert 20110501

• Human immunodeficiency virus therapeutics and pharmacogenomics.

  Indian journal of human genetics 20110501

• Relationship between neck circumference and cardiometabolic parameters in HIV-infected and non-HIV-infected adults.

  Diabetes care 20110401

• No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110401

• Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.

  Pharmacotherapy 20110401

• Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.

  Pharmacogenomics 20110401

• Clinical management of HIV drug resistance.

  Viruses 20110401

• Clinical applications of drug desensitization in the Asia-Pacific region.

  Asia Pacific allergy 20110401

• HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

  Current HIV/AIDS reports 20110301

• Pharmacogenetics of cutaneous adverse drug reactions.

  The Journal of dermatology 20110301

• Drug hypersensitivity: pharmacogenetics and clinical syndromes.

  The Journal of allergy and clinical immunology 20110301

• Type 2 diabetes and impaired glucose tolerance in two young adults infected with HIV early in life.

  Diabetes care 20110301

• Inflammation in depression: is adiposity a cause?

  Dialogues in clinical neuroscience 20110301

• Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing.

  AIDS research and human retroviruses 20110201

• Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting.

  AIDS and behavior 20110201

• Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.

  Tropical medicine & international health : TM & IH 20110201

• Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.

  Current atherosclerosis reports 20110201

• Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

  The Journal of antimicrobial chemotherapy 20110201

• High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110201

• Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.

  Current infectious disease reports 20110201

• From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

  International journal of clinical pharmacy 20110201

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20110201

• Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20110125

• Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110115

• Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

  The Journal of infectious diseases 20110115

• Impact of antiretroviral treatment on (13) C-methionine metabolism as a marker of hepatic mitochondrial function: a longitudinal study.

  HIV medicine 20110101

• The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study.

  Current medical research and opinion 20110101

• The toxicogenetics of antiretroviral therapy: the evil inside.

  Current medicinal chemistry 20110101

• Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions.

  Journal of biopharmaceutical statistics 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.

  BMC medicine 20110101

• K70Q adds high-level tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism.

  PloS one 20110101

• A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.

  Virology journal 20110101

• Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.

  BMC infectious diseases 20110101

• A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

  PloS one 20110101

• Clinical use of CCR5 inhibitors in HIV and beyond.

  Journal of translational medicine 20110101

• Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.

  BMC infectious diseases 20110101

• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.

  Journal of the International AIDS Society 20110101

• Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs.

  BMC infectious diseases 20110101

• Antiretroviral therapy-associated acute motor and sensory axonal neuropathy.

  Case reports in neurology 20110101

• HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.

  Lipids in health and disease 20110101

• Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

  AIDS research and therapy 20110101

• Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study.

  BMC infectious diseases 20110101

• Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.

  PloS one 20110101

• Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.

  PloS one 20110101

• Structure-based drug design and AutoDock study of potential protein tyrosine kinase inhibitors.

  Bioinformation 20110101

• 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.

  PloS one 20110101

• Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho.

  PloS one 20110101

• High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia.

  Journal of the International AIDS Society 20110101

• Machine learning on normalized protein sequences.

  BMC research notes 20110101

• Comparison of intima-media thickness and ophthalmic artery resistance index for assessing subclinical atherosclerosis in HIV-1-infected patients.

  Cardiovascular ultrasound 20110101

• Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.

  Internal medicine (Tokyo, Japan) 20110101

• Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program.

  PloS one 20110101

• The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.

  European journal of medical research 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia.

  AIDS research and treatment 20110101

• Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

  AIDS research and treatment 20110101

• Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.

  BMC infectious diseases 20110101

• Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.

  PloS one 20110101

• HIV-Associated Tuberculosis in the Newborn and Young Infant.

  International journal of pediatrics 20110101

• HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy.

  PloS one 20110101

• [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].

  Enfermedades infecciosas y microbiologia clinica 20110101

• Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

  PloS one 20110101

• Safety and tolerability of antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20110101

• Outcome assessment of a dedicated HIV positive health care worker clinic at a central hospital in Malawi: a retrospective observational study.

  PloS one 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• Personalizing carbamazepine therapy.

  Genome medicine 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.

  Molecular brain 20110101

• Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol.

  PloS one 20110101

• A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.

  PloS one 20110101

• Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy.

  Patient preference and adherence 20110101

• Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

  PloS one 20110101

• Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.

  Antiviral therapy 20110101

• Immune reconstitution and inflammatory syndrome due to disseminated tuberculosis in a case of human immunodeficiency virus 2 infection.

  Indian journal of pharmacology 20110101

• Cutaneous drug hypersensitivity: immunological and genetic perspective.

  Indian journal of dermatology 20110101

• An Apple-core Lesion in the Colon: An Infectious Etiology.

  Journal of global infectious diseases 20110101

• Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.

  PloS one 20110101

• Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.

  PloS one 20110101

• Non-cirrhotic portal hypertension in human immunodeficiency virus-infected patients: a new challenge in antiretroviral therapy era.

  The open AIDS journal 20110101

• BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression.

  Journal of transplantation 20110101

• Predictors of Weight Change in Male HIV-Positive Injection Drug Users Initiating Antiretroviral Therapy in Hanoi, Vietnam.

  AIDS research and treatment 20110101

• Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

  PloS one 20110101

• Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

  BMC pediatrics 20110101

• Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.

  PloS one 20110101

• Graves' Disease as a Manifestation of Immune Reconstitution in HIV-Infected Individuals after Initiation of Highly Active Antiretroviral Therapy.

  AIDS research and treatment 20110101

• Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.

  BMC women's health 20110101

• Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101

• Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

  Patient preference and adherence 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• Nephrotoxicity of HAART.

  AIDS research and treatment 20110101

• Pharmacogenomic technologies: a necessary 'luxury' for better global public health?

  Globalization and health 20110101

• HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high.

  PloS one 20110101

• Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.

  PloS one 20110101

• Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.

  Antiviral therapy 20110101

• Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy.

  Biology direct 20110101

• Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review.

  Journal of medical case reports 20110101

• Increased prevalence of albuminuria in HIV-infected adults with diabetes.

  PloS one 20110101

• Noninvasive coronary imaging for atherosclerosis in human immunodeficiency virus infection.

  Current problems in diagnostic radiology 20110101

• Primary cutaneous B-cell lymphoma successfully treated with highly active antiretroviral therapy alone: a case report and review of the literature.

  Indian journal of dermatology 20110101

• Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

  BMC infectious diseases 20110101

• A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

  Globalization and health 20110101

• Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.

  Antiviral therapy 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Human immunodeficiency virus endocrinopathy.

  Indian journal of endocrinology and metabolism 20110101

• Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.

  PloS one 20110101

• Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.

  PloS one 20110101

• Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.

  BMC infectious diseases 20110101

• Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review.

  BMC medical research methodology 20110101

• Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.

  PloS one 20110101

• Optimal antiviral switching to minimize resistance risk in HIV therapy.

  PloS one 20110101

• The impact of pharmacogenetics in the treatment of allergic disease and asthma.

  Missouri medicine 20110101

• Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city.

  Nigerian medical journal : journal of the Nigeria Medical Association 20110101

• It is time to consider third-line options in antiretroviral-experienced paediatric patients?

  Journal of the International AIDS Society 20110101

• Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Role of raltegravir in the management of HIV-1 infection.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.

  European journal of medical research 20110101

• Proteomic signatures of human oral epithelial cells in HIV-infected subjects.

  PloS one 20110101

• Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women.

  PloS one 20110101

• Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

  PloS one 20110101

• Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

  Retrovirology 20110101

• Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis.

  Cardiovascular diabetology 20110101

• Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.

  Antiviral therapy 20110101

• A case of cholestatic hepatitis associated with histologic features of acute cholangitis.

  International journal of general medicine 20110101

• Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.

  ClinicoEconomics and outcomes research : CEOR 20110101

• [New enzymatic strategies for enantiomers of lactams and amino acids].

  Acta pharmaceutica Hungarica 20110101

• Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.

  PloS one 20110101

• Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.

  PloS one 20110101

• Nanomedicine as an emerging approach against intracellular pathogens.

  International journal of nanomedicine 20110101

• Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

  Patient preference and adherence 20110101

• Lipodystrophy in HIV patients: its challenges and management approaches.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Pharmacogenomics: what is next?

  Frontiers in pharmacology 20110101

• Synthesis and Inhibiting Activity of Some 4-Hydroxycoumarin Derivatives on HIV-1 Protease.

  ISRN pharmaceutics 20110101

• Allergic diseases in the elderly.

  Clinical and translational allergy 20110101

• Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.

  Dermatologic therapy 20110101

• Intractable chronic vulval ulceration presenting as immune reconstitution inflammatory syndrome in a treatment-failure patient: a case observation.

  Case reports in obstetrics and gynecology 20110101

• Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.

  Journal of acquired immune deficiency syndromes (1999) 20101215

• Genetic determinants of HSP70 gene expression following heat shock.

  Human molecular genetics 20101215

• HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

  The Journal of infectious diseases 20101215

• HLA-B*5701 testing to predict abacavir hypersensitivity.

  PLoS currents 20101207

• [HLA-B*5701 and abacavir hypersensitivity reaction].

  Pathologie-biologie 20101201

• Estimating causal effects using prior information on nontrial treatments.

  Clinical trials (London, England) 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.

  The Indian journal of medical research 20101201

• Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai.

  The Indian journal of medical research 20101201

• HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.

  Georgian medical news 20101201

• Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.

  AIDS (London, England) 20101113

• Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.

  Enfermedades infecciosas y microbiologia clinica 20101101

• HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium.

  Diabetes 20101101

• Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

  The Journal of antimicrobial chemotherapy 20101101

• HIV-1 induces DCIR expression in CD4+ T cells.

  PLoS pathogens 20101101

• FDA notifications. FDA approves generic abacavir.

  AIDS alert 20101101

• Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101015

• Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.

  Journal of medicinal chemistry 20101014

• Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

  European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 20101001

• Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R.

  The Journal of infection 20101001

• Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101001

• The impact of gender and anchor drugs on TDF renal toxicity.

  Journal of acquired immune deficiency syndromes (1999) 20101001

• Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.

  Pharmacotherapy 20101001

• A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.

  Electrophoresis 20101001

• Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk.

  AIDS (London, England) 20100924

• HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20100901

• Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

  Journal of acquired immune deficiency syndromes (1999) 20100901

• Predicting and preventing acute drug-induced liver injury: what's new in 2010?

  Expert opinion on drug metabolism & toxicology 20100901

• Use of abacavir in 30 HIV-infected children from Durban, South Africa: report from a pilot study.

  The Pediatric infectious disease journal 20100901

• Development and validation of a selective and rapid LC-MS-MS method for the quantification of abacavir in human plasma.

  Journal of chromatographic science 20100901

• Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

  AIDS (London, England) 20100824

• First report of abacavir associated with hypoglycemia.

  AIDS (London, England) 20100824

• Abacavir and cardiovascular risk: reviewing the evidence.

  Current HIV/AIDS reports 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

  The Journal of antimicrobial chemotherapy 20100801

• Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100801

• [Pharmacogenetics].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20100801

• Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi.

  PLoS medicine 20100801

• The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

  PLoS medicine 20100801

• Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report.

  Viruses 20100801

• Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

  Archives of internal medicine 20100726

• Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.

  AIDS (London, England) 20100717

• Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

  Antimicrobial agents and chemotherapy 20100701

• Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20100701

• Pharmacogenetics of drug hypersensitivity.

  Pharmacogenomics 20100701

• Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

  Journal of the National Cancer Institute 20100602

• Connection domain mutations in treatment-experienced patients in the OPTIMA trial.

  Journal of acquired immune deficiency syndromes (1999) 20100601

• Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir.

  Cardiovascular toxicology 20100601

• Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation.

  AIDS (London, England) 20100601

• Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.

  AIDS patient care and STDs 20100601

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20100601

• Does abacavir use influence HCV treatment response?

  Journal watch. AIDS clinical care 20100601

• Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.

  AIDS (London, England) 20100515

• Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.

  Medical mycology 20100501

• Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.

  HIV medicine 20100501

• Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

  HIV medicine 20100501

• An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe.

  Pharmacogenetics and genomics 20100501

• Economic modeling of HIV treatments.

  Current opinion in HIV and AIDS 20100501

• [Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].

  MMW Fortschritte der Medizin 20100429

• Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100415

• Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.

  Pharmacogenomics 20100401

• Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management.

  AIDS (London, England) 20100327

• Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

  The Cochrane database of systematic reviews 20100317

• Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.

  AIDS (London, England) 20100313

• A controlled trial of initial antiviral regimens for HIV-1 infection.

  The New England journal of medicine 20100304

• Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.

  HIV medicine 20100301

• Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.

  HIV medicine 20100301

• A model-based approach to dose selection in early pediatric development.

  Clinical pharmacology and therapeutics 20100301

• Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance?

  Environmental science & technology 20100301

• Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry.

  Analytical chemistry 20100301

• Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.

  British journal of clinical pharmacology 20100301

• The silent epidemic of exclusive university licensing policies on compounds for neglected diseases and beyond.

  PLoS neglected tropical diseases 20100301

• [Durability and tolerability of long-term nevirapine-based HAART].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20100301

• Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

  HIV medicine 20100201

• Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).

  Antiviral research 20100201

• Abacavir and cardiovascular risk.

  Current opinion in infectious diseases 20100201

• Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

  The Journal of antimicrobial chemotherapy 20100201

• Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories.

  Genetic testing and molecular biomarkers 20100201

• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

  The Journal of infectious diseases 20100201

• Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.

  The Annals of pharmacotherapy 20100201

• HIV treatment information.

  Project Inform perspective 20100201

• Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.

  AIDS (London, England) 20100128

• Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

  Archives of internal medicine 20100111

• Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

  Lancet (London, England) 20100109

• Pharmacogenetics of antiretrovirals.

  Antiviral research 20100101

• Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

  Tissue antigens 20100101

• Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.

  The Journal of infectious diseases 20100101

• Pharmacogenetics of idiosyncratic adverse drug reactions.

  Handbook of experimental pharmacology 20100101

• Are patents impeding medical care and innovation?

  PLoS medicine 20100101

• Modelling imperfect adherence to HIV induction therapy.

  BMC infectious diseases 20100101

• Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient.

  BMC gastroenterology 20100101

• HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008.

  European journal of medical research 20100101

• Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

  Patient preference and adherence 20100101

• Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.

  Antiviral therapy 20100101

• The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.

  Antiviral therapy 20100101

• Extracting causal relations on HIV drug resistance from literature.

  BMC bioinformatics 20100101

• Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

  PloS one 20100101

• Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics.

  The open AIDS journal 20100101

• Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.

  Advances in therapy 20100101

• Successful treatment of HIV-associated multicentric Castleman's disease and multiple organ failure with rituximab and supportive care: a case report.

  Journal of medical case reports 20100101

• Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review.

  BMC infectious diseases 20100101

• Technology Development Through Pooling ARV Drug Patents: A Vision from China.

  The open AIDS journal 20100101

• Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study.

  PloS one 20100101

• Abacavir/lamivudine combination in the treatment of HIV: a review.

  Therapeutics and clinical risk management 20100101

• Pharmacogenomics and personalized medicine: lost in translation?

  Genome medicine 20100101

• Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.

  AIDS research and therapy 20100101

• High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia.

  Journal of the International AIDS Society 20100101

• When to start antiretroviral therapy in resource-limited settings: a human rights analysis.

  BMC international health and human rights 20100101

• Pharmacogenomics: bridging the gap between science and practice.

  Journal of the American Pharmacists Association : JAPhA 20100101

• Progress on antiangiogenic therapy for patients with malignant glioma.

  Journal of oncology 20100101

• Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir.

  AIDS research and therapy 20100101

• Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.

  HIV clinical trials 20100101

• The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.

  PloS one 20100101

• HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the 'test-and-treat' approach to reduce HIV transmission.

  PloS one 20100101

• Increasing rates of obesity among HIV-infected persons during the HIV epidemic.

  PloS one 20100101

• 'I will not let my HIV status stand in the way.' Decisions on motherhood among women on ART in a slum in Kenya- a qualitative study.

  BMC women's health 20100101

• Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.

  European journal of medical research 20100101

• HAART and the liver: friend or foe?

  European journal of medical research 20100101

• The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.

  European journal of medical research 20100101

• Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision.

  Therapeutics and clinical risk management 20100101

• Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.

  Globalization and health 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.

  Antiviral therapy 20100101

• Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.

  Antiviral therapy 20100101

• One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects.

  Patient preference and adherence 20100101

• Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.

  AIDS research and therapy 20100101

• Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

  BMC health services research 20100101

• Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.

  PloS one 20100101

• Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.

  PloS one 20100101

• Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.

  PloS one 20100101

• Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.

  HIV clinical trials 20100101

• Transcriptome analysis of monocyte-HIV interactions.

  Retrovirology 20100101

• Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study.

  BMC infectious diseases 20100101

• Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany.

  European journal of medical research 20100101

• Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?

  European journal of medical research 20100101

• Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.

  AIDS research and therapy 20100101

• The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.

  BMC infectious diseases 20100101

• Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.

  PharmacoEconomics 20100101

• Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.

  BMC infectious diseases 20100101

• Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study.

  Antiviral therapy 20100101

• Making it happen, level 2.

  Global health action 20100101

• Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.

  PloS one 20100101

• Abacavir and CVD--more data but no consensus. Studies this year were evenly split, leaving patients and clinicians with few answers.

  Journal watch. AIDS clinical care 20100101

• Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.

  PloS one 20100101

• Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study.

  AIDS research and therapy 20100101

• [Analysis of the duration of and reasons for changing the first combination of antiretroviral therapy].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20100101

• Secular trends in pediatric antiretroviral treatment programs in rural and urban Zambia: a retrospective cohort study.

  BMC pediatrics 20100101

• The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.

  PloS one 20100101

• Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children.

  Journal of the International AIDS Society 20100101

• [Genetic variations affect drug safety and efficacy].

  Nederlands tijdschrift voor geneeskunde 20100101

• Diagnosis of systemic toxoplasmosis with HIV infection using DNA extracted from paraffin-embedded tissue for polymerase chain reaction: a case report.

  Journal of medical case reports 20100101

• Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.

  Antiviral therapy 20100101

• Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.

  HIV clinical trials 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women.

  Journal of the International AIDS Society 20100101

• Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.

  PloS one 20100101

• Anti-retroviral therapy-induced status epilepticus in 'pseudo-HIV serodeconversion'.

  General hospital psychiatry 20100101

• Pharmacogenetics and pharmacogenomics: practical applications in routine medical practice.

  Genome medicine 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia.

  PloS one 20100101

• A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences.

  AIDS research and therapy 20100101

• The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

  BMC pediatrics 20100101

• Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

  European journal of medical research 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire.

  PloS one 20100101

• Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study.

  PloS one 20100101

• Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

  PloS one 20100101

• Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.

  PloS one 20100101

• Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen.

  AIDS research and therapy 20100101

• Frequency of HIV-1 viral load monitoring of patients initially successfully treated with combination antiretroviral therapy.

  PloS one 20100101

• A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial.

  HIV clinical trials 20100101

• Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).

  HIV clinical trials 20100101

• Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

  Antiviral therapy 20100101

• The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines.

  PloS one 20100101

• Genetic screening for metabolic and age-related complications in HIV-infected persons.

  F1000 medicine reports 20100101

• Proteochemometric modeling of the susceptibility of mutated variants of the HIV-1 virus to reverse transcriptase inhibitors.

  PloS one 20100101

• Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.

  BMC infectious diseases 20100101

• HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20100101

• Computational Analysis of Molecular Interaction Networks Underlying Change of HIV-1 Resistance to Selected Reverse Transcriptase Inhibitors.

  Bioinformatics and biology insights 20100101

• A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

  HIV clinical trials 20100101

• Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data.

  The open AIDS journal 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• Pharmacogenetics - challenges and opportunities ahead.

  Frontiers in pharmacology 20100101

• Beyond the black box: drug- and device-associated hypersensitivity events.

  Drug, healthcare and patient safety 20100101

• HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.

  Mediterranean journal of hematology and infectious diseases 20100101

• Patent protection strategies.

  Journal of pharmacy & bioallied sciences 20100101

• Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Long-term treatment of patients with HIV-1: the role of atazanavir.

  HIV/AIDS (Auckland, N.Z.) 20100101

• New and emerging agents in the management of lipodystrophy in HIV-infected patients.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Genomes, populations and diseases: ethnic genomics and personalized medicine.

  Acta naturae 20100101

• Two-dimensional LC-MS/MS determination of antiretroviral drugs in rat serum and urine.

  Journal of pharmaceutical and biomedical analysis 20091205

• Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

  The New England journal of medicine 20091203

• Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20091201

• Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus.

  Clinical and experimental dermatology 20091201

• Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.

  The Pediatric infectious disease journal 20091201

• The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy.

  AIDS patient care and STDs 20091201

• Abacavir and lamivudine combination.

  Expert opinion on drug metabolism & toxicology 20091201

• Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure.

  Journal of Korean medical science 20091201

• Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.

  AIDS research and human retroviruses 20091201

• Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091115

• The art of managing human immunodeficiency virus infection: a balancing act.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091115

• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  Journal of pharmaceutical sciences 20091101

• Genetics and the general physician: insights, applications and future challenges.

  QJM : monthly journal of the Association of Physicians 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.

  AIDS patient care and STDs 20091101

• PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

  HIV medicine 20091101

• Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.

  HIV medicine 20091101

• Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

  Infection 20091001

• A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.

  Journal of medical virology 20091001

• Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.

  HIV medicine 20091001

• A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh.

  Indian journal of pharmacology 20091001

• Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.

  Journal watch. AIDS clinical care 20091001

• Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.

  AIDS (London, England) 20090924

• A1C underestimates glycemia in HIV infection.

  Diabetes care 20090901

• B-mode ultrasound study of carotid plaques in HIV-positive patients to detect the presence of inflammatory endothelial lesions.

  Current HIV research 20090901

• Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.

  Antimicrobial agents and chemotherapy 20090901

• Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.

  Journal of medical virology 20090901

• Virological response to initial antiretroviral regimens containing abacavir or tenofovir.

  The Journal of infectious diseases 20090901

• Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.

  Arteriosclerosis, thrombosis, and vascular biology 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

  Journal of acquired immune deficiency syndromes (1999) 20090901

• [Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20090901

• FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.

  AIDS alert 20090901

• [Cardiovascular risk factors associated with antiretroviral therapy].

  Enfermedades infecciosas y microbiologia clinica 20090901

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• Drug-induced liver injury: what was new in 2008?

  Expert opinion on drug metabolism & toxicology 20090801

• Abacavir methanol 2.5-solvate.

  Acta crystallographica. Section E, Structure reports online 20090801

• Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

  AIDS (London, England) 20090731

• The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells.

  International journal of cancer 20090701

• Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals.

  Antimicrobial agents and chemotherapy 20090701

• A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.

  HIV medicine 20090701

• The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).

  AIDS research and human retroviruses 20090701

• Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome.

  PLoS computational biology 20090701

• Renal transplantation in a HIV positive patient.

  Indian journal of nephrology 20090701

• Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.

  Transactions of the Royal Society of Tropical Medicine and Hygiene 20090601

• Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world.

  International journal of STD & AIDS 20090601

• HLA and drug-induced toxicity.

  Current opinion in molecular therapeutics 20090601

• Improving drug safety by locating genetic markers for hypersensitivity reactions.

  The Medical journal of Australia 20090601

• How much fat loss is needed for lipoatrophy to become clinically evident?

  AIDS research and human retroviruses 20090601

• The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

  Antiviral research 20090501

• Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

  The Journal of antimicrobial chemotherapy 20090501

• Resistance to antiretrovirals in HIV-infected pregnant women.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20090501

• Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?

  Current HIV research 20090501

• Clinical use of pharmacogenomic tests in 2009.

  The Clinical biochemist. Reviews 20090501

• [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].

  MMW Fortschritte der Medizin 20090430

• Screening and monitoring antiretrovirals and antivirals in the serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography.

  Journal of chromatography. A 20090417

• Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.

  Journal of acquired immune deficiency syndromes (1999) 20090415

• Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection.

  Journal of chromatography. A 20090410

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.

  Clinical pharmacology and therapeutics 20090401

• Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.

  The Journal of pharmacology and experimental therapeutics 20090401

• Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease.

  Infectious disorders drug targets 20090401

• Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative.

  International journal of STD & AIDS 20090401

• Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

  AIDS research and human retroviruses 20090401

• CROI 2009: a few key presentations on antiretroviral therapy.

  The AIDS reader 20090401

• Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

  The AIDS reader 20090401

• Report from the 16th Conference on Retroviruses and Opportunistic Infections. Continued concern about abacavir and cardiovascular risk.

  Journal watch. AIDS clinical care 20090401

• Aid agencies condemn drug confiscation.

  BMJ (Clinical research ed.) 20090311

• Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.

  Diabetes care 20090301

• Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells.

  The American journal of pathology 20090301

• The impact of pharmacogenetics on HIV therapy.

  International journal of STD & AIDS 20090301

• Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20090301

• [Treatment of chronic hepatitis C in HIV-infected patients].

  Gastroenterologie clinique et biologique 20090301

• Hepatitis B in HIV patients: what is the current treatment and what are the challenges?

  Journal of HIV therapy 20090301

• Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.

  Bioorganic & medicinal chemistry 20090215

• Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.

  The pharmacogenomics journal 20090201

• In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.

  Journal of medical virology 20090201

• Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090201

• Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.

  Pharmacogenomics 20090201

• FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.

  AIDS alert 20090201

• FDA notifications. Abacavir approved for pediatric patients.

  AIDS alert 20090201

• [Atazanavir-induced nephrolithiasis].

  Enfermedades infecciosas y microbiologia clinica 20090201

• [Pharmacovigilance and teratovigilance 2008].

  Revue medicale suisse 20090114

• Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.

  AIDS (London, England) 20090102

• The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090101

• Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

  The Journal of infectious diseases 20090101

• Metabolic abnormalities associated with HIV infection and antiretroviral therapy.

  Current infectious disease reports 20090101

• The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

  PPAR research 20090101

• Invasive disease caused by nontuberculous mycobacteria, Tanzania.

  Emerging infectious diseases 20090101

• Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

  PPAR research 20090101

• An analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitors.

  PLoS computational biology 20090101

• Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?

  AIDS research and therapy 20090101

• Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance.

  Retrovirology 20090101

• Top stories of 2008. Abacavir turmoil.

  AIDS clinical care 20090101

• Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.

  AIDS clinical care 20090101

• Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.

  PloS one 20090101

• Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria.

  Journal of the International AIDS Society 20090101

• Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

  PloS one 20090101

• Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?

  Antiviral therapy 20090101

• Successful translation of pharmacogenetics into the clinic: the abacavir example.

  Molecular diagnosis & therapy 20090101

• A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).

  AIDS research and therapy 20090101

• Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study).

  HIV clinical trials 20090101

• Physical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling.

  BMC public health 20090101

• Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

  European journal of medical research 20090101

• Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?

  AIDS research and therapy 20090101

• Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.

  AIDS research and therapy 20090101

• Ankle-brachial index in HIV infection.

  AIDS research and therapy 20090101

• Life-threatening hemorrhage following subcutaneous heparin therapy.

  Therapeutics and clinical risk management 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• Guilt by association.

  Genome biology 20090101

• The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

  Retrovirology 20090101

• Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

  PloS one 20090101

• Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies.

  HIV clinical trials 20090101

• Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

  HIV clinical trials 20090101

• Changes in hematological parameters after switching treatment of HIV-infected patients from zidovudine to abacavir or tenofovir DF.

  HIV clinical trials 20090101

• Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

  BMC infectious diseases 20090101

• HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.

  Critical reviews in clinical laboratory sciences 20090101

• Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study.

  AIDS research and therapy 20090101

• Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).

  European journal of medical research 20090101

• Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

  PloS one 20090101

• Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

  PloS one 20090101

• Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.

  BMC infectious diseases 20090101

• Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.

  HIV clinical trials 20090101

• Update on cardiovascular complications in HIV infection.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy.

  BMC infectious diseases 20090101

• [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Planning for translational research in genomics.

  Genome medicine 20090101

• Mortality after hospitalization for pneumonia among individuals with HIV, 1995-2008: a Danish cohort study.

  PloS one 20090101

• Epitope mapping of HIV-specific CD8+ T cells in a cohort dominated by clade A1 infection.

  PloS one 20090101

• Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

  Retrovirology 20090101

• Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma.

  Biologics : targets & therapy 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models.

  Diabetology & metabolic syndrome 20090101

• Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report.

  Journal of medical case reports 20090101

• HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

  PloS one 20090101

• Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy.

  Journal of biomedicine & biotechnology 20090101

• Treatment interruption after pregnancy: effects on disease progression and laboratory findings.

  Infectious diseases in obstetrics and gynecology 20090101

• The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia.

  The open virology journal 20090101

• Factors influencing global antiretroviral procurement prices.

  BMC public health 20090101

• German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

  European journal of medical research 20090101

• Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.

  PloS one 20090101

• Pharmacogenomic insights into treatment and management of statin-induced myopathy.

  Genome medicine 20090101

• Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.

  HIV clinical trials 20090101

• A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome.

  Bioinformatics and biology insights 20090101

• The treatment of chronic hepatitis C virus infection in HIV co-infection.

  European journal of medical research 20090101

• Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

  Core evidence 20090101

• Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy.

  F1000 medicine reports 20090101

• Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity.

  BMJ case reports 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacogenetics: implementing personalized medicine.

  Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 20090101

• Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.

  The pharmacogenomics journal 20081201

• Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.

  The Journal of antimicrobial chemotherapy 20081201

• Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081201

• Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.

  Genetics in medicine : official journal of the American College of Medical Genetics 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.

  AIDS clinical care 20081201

• Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.

  Therapeutics and clinical risk management 20081201

• Abacavir: pretreatment screening: warning. Encouraging method but uncertainties remain.

  Prescrire international 20081201

• Abacavir, Didanosine: myocardial infarction.

  Prescrire international 20081201

• Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy.

  AIDS (London, England) 20081130

• Abacavir-induced hepatotoxicity: a report of two cases.

  AIDS (London, England) 20081130

• Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy.

  AIDS care 20081101

• HIV pharmacogenetics in clinical practice: recent achievements and future challenges.

  Current HIV research 20081101

• Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

  AIDS (London, England) 20081101

• Generic lamivudine and abacavir approved.

  AIDS patient care and STDs 20081101

• FDA notifications. Abacavir tablet approved for pediatric patients.

  AIDS alert 20081101

• [HIV tests].

  Rinsho byori. The Japanese journal of clinical pathology 20081101

• Abacavir-induced febrile agranulocytosis and anaemia.

  AIDS (London, England) 20081018

• Validity and comparison of two measures of days supply in Medicaid claims data.

  Pharmacoepidemiology and drug safety 20081001

• HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.

  The Journal of antimicrobial chemotherapy 20081001

• Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.

  The Journal of antimicrobial chemotherapy 20081001

• Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.

  HIV medicine 20081001

• Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.

  AIDS patient care and STDs 20081001

• Comment: Abacavir hypersensitivity reaction: an update.

  The Annals of pharmacotherapy 20081001

• Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.

  AIDS (London, England) 20081001

• The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

  AIDS (London, England) 20081001

• Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

  AIDS research and human retroviruses 20081001

• Current trends in screening across ethnicities for hypersensitivity to abacavir.

  Pharmacogenomics 20081001

• FDA notifications. Generic abacavir and lamivudine combo approved.

  AIDS alert 20081001

• [Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].

  Recenti progressi in medicina 20081001

• Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

  Therapeutics and clinical risk management 20081001

• The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir.

  The Journal of infectious diseases 20080915

• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

  AIDS (London, England) 20080912

• The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research.

  American journal of human genetics 20080912

• Abacavir and increased risk of myocardial infarction.

  Lancet (London, England) 20080906

• Abacavir and increased risk of myocardial infarction.

  Lancet (London, England) 20080906

• Abacavir and increased risk of myocardial infarction.

  Lancet (London, England) 20080906

• Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

  British journal of cancer 20080902

• A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

  Antiviral research 20080901

• Cariogenic and erosive potential of the medication used by HIV-infected children: pH and sugar concentration.

  Community dental health 20080901

• FDA notifications. Abacavir package insert changes approved. Hypersensitivity, other issues addressed.

  AIDS alert 20080901

• HIV infection in the elderly.

  Clinical interventions in aging 20080901

• Abacavir controversy continues to brew.

  Project Inform perspective 20080901

• Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus.

  International journal of emergency medicine 20080901

• First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.

  AIDS (London, England) 20080820

• Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.

  HIV medicine 20080801

• The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

  Journal of acquired immune deficiency syndromes (1999) 20080801

• Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.

  International journal of STD & AIDS 20080801

• Labeling changes for abacavir.

  AIDS patient care and STDs 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.

  The AIDS reader 20080801

• Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients.

  Therapeutics and clinical risk management 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• An unusual abacavir reaction.

  AIDS (London, England) 20080731

• Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative.

  AIDS (London, England) 20080731

• A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.

  Journal of virological methods 20080701

• Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.

  The Journal of infection 20080701

• Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.

  PLoS medicine 20080701

• Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.

  AIDS research and human retroviruses 20080701

• Abacavir hypersensitivity.

  The New England journal of medicine 20080605

• Abacavir hypersensitivity.

  The New England journal of medicine 20080605

• Resampling-based multiple testing methods with covariate adjustment: application to investigation of antiretroviral drug susceptibility.

  Biometrics 20080601

• BCRP/ABCG2 in the placenta: expression, function and regulation.

  Pharmaceutical research 20080601

• Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

  Immunity 20080601

• Pharmacogenomics of antiretrovirals.

  Recent patents on anti-infective drug discovery 20080601

• Atriplatrade mark - HIV therapy in one pill.

  Therapeutics and clinical risk management 20080601

• [Are all analogue combinations equal?].

  Enfermedades infecciosas y microbiologia clinica 20080601

• [Current role of tenofovir in clinical medicine].

  Enfermedades infecciosas y microbiologia clinica 20080601

• Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?

  African health sciences 20080601

• A review of drug patch testing and implications for HIV clinicians.

  AIDS (London, England) 20080531

• [Metabolic side effects of antiretroviral therapy].

  Nederlands tijdschrift voor geneeskunde 20080531

• Abacavir and warfarin modulate allosterically kinetics of NO dissociation from ferrous nitrosylated human serum heme-albumin.

  Biochemical and biophysical research communications 20080502

• Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• Cardiac tamponade: an unusual complication of simultaneous treatment of tuberculosis and HIV.

  Southern medical journal 20080501

• Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• FDA reviewing safety of Ziagen and Videx.

  The AIDS reader 20080501

• [Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].

  Lakartidningen 20080501

• FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.

  AIDS alert 20080501

• [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].

  Enfermedades infecciosas y microbiologia clinica 20080501

• [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].

  Enfermedades infecciosas y microbiologia clinica 20080501

• [Applicability of pharmacogenetic studies in daily clinical practice].

  Enfermedades infecciosas y microbiologia clinica 20080501

• Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs.

  Current opinion in HIV and AIDS 20080501

• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

  Lancet (London, England) 20080426

• Abacavir and the potential risk of myocardial infarction.

  Lancet (London, England) 20080426

• HIV study yields unexpected preliminary efficacy results.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080415

• Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080415

• Diagnosis and management of HIV drug hypersensitivity.

  The Journal of allergy and clinical immunology 20080401

• Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.

  AIDS patient care and STDs 20080401

• Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401

• Heart attack risk with abacavir and didanosine.

  AIDS patient care and STDs 20080401

• High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080401

• 'One pill, once daily': what clinicians need to know about Atriplatrade mark.

  Therapeutics and clinical risk management 20080401

• Report from the 15th Retrovirus Conference. Is abacavir therapy associated with MI risk?

  AIDS clinical care 20080401

• Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.

  AIDS clinical care 20080401

• Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation.

  Clinical immunology (Orlando, Fla.) 20080301

• Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301

• Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.

  Pharmacotherapy 20080301

• Abacavir hypersensitivity reaction: an update.

  The Annals of pharmacotherapy 20080301

• Abacavir and didanosine increase the risk of heart attack.

  AIDS patient care and STDs 20080301

• Genomics and biology come together to fight HIV.

  PLoS biology 20080301

• Anti-HIV agents. Controversial findings on abacavir and heart attacks.

  TreatmentUpdate 20080301

• HLA-B*5701 screening for hypersensitivity to abacavir.

  The New England journal of medicine 20080207

• Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.

  The New England journal of medicine 20080207

• Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.

  Journal of mass spectrometry : JMS 20080201

• Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

  Antimicrobial agents and chemotherapy 20080201

• Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.

  HIV medicine 20080201

• Pharmacogenetics and the potential for the individualization of antiretroviral therapy.

  Current opinion in infectious diseases 20080201

• Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.

  European journal of clinical pharmacology 20080201

• A case of acute renal failure associated with diffuse infiltrative lymphocytosis syndrome.

  Nature clinical practice. Nephrology 20080201

• A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort.

  AIDS patient care and STDs 20080201

• Pharmacogenetic information derived from analysis of HLA alleles.

  Pharmacogenomics 20080201

• PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.

  Pharmaceutical statistics 20080101

• Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

  Antimicrobial agents and chemotherapy 20080101

• Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20080101

• Electrochemical determination of HIV drug Abacavir based on its reduction.

  Analytical chemistry 20080101

• Treatment options for lipodystrophy in HIV-positive patients.

  Expert opinion on pharmacotherapy 20080101

• Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

  Drugs 20080101

• Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response.

  HIV medicine 20080101

• Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

  HIV clinical trials 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Implementation and effectiveness of antiretroviral therapy in Greenland.

  Emerging infectious diseases 20080101

• The cost of antiretroviral therapy in Haiti.

  Cost effectiveness and resource allocation : C/E 20080101

• Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).

  Tropical medicine & international health : TM & IH 20080101

• Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

  BMC infectious diseases 20080101

• Efficacy and safety of once-daily regimens in the treatment of HIV infection.

  Drugs 20080101

• Acute renal failure in an AIDS patient on tenofovir: a case report.

  Journal of medical case reports 20080101

• Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues.

  Antiviral therapy 20080101

• New formulations approved for children.

  AIDS patient care and STDs 20080101

• A review of the pharmacokinetics of abacavir.

  Clinical pharmacokinetics 20080101

• Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.

  Antiviral therapy 20080101

• Cytokine profiling in abacavir hypersensitivity patients.

  Antiviral therapy 20080101

• [Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS].

  Przeglad epidemiologiczny 20080101

• Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.

  HIV clinical trials 20080101

• Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.

  Antiviral therapy 20080101

• Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.

  BMC infectious diseases 20080101

• Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.

  PloS one 20080101

• Medical management of human immunodeficiency virus infection.

  Indian journal of ophthalmology 20080101

• Incidence of abacavir hypersensitivity reactions in euroSIDA.

  Antiviral therapy 20080101

• Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy.

  PloS one 20080101

• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.

  The open AIDS journal 20080101

• Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir.

  Pharmacology 20080101

• Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.

  BMC infectious diseases 20080101

• A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection.

  AIDS research and therapy 20080101

• Successful treatment with azithromycin and rifampicin of penicillin and cephalosporin insensitive pneumococcal osteomyelitis in a child with HIV infection: a case report.

  Cases journal 20080101

• Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.

  PloS one 20080101

• Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity.

  Current pharmaceutical design 20080101

• Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

  Antiviral therapy 20080101

• Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report.

  Journal of medical case reports 20080101

• XVII International AIDS Conference--Mexico City, August 3-8, 2008. Can Ziagen hurt your heart? Research presented at the International AIDS Conference weighs in on the controversy.

  Positively aware : the monthly journal of the Test Positive Aware Network 20080101

• Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.

  AIDS reviews 20080101

• Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.

  PloS one 20080101

• Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.

  Antiviral therapy 20080101

• Harnessing pharmacogenomics to tackle resistance to the 'nucleoside reverse trancripatse inhibitor' backbone of highly active antiretroviral therapy in resource limited settings.

  The open AIDS journal 20080101

• Abstracts of papers presented at the 2008 pittsburgh conference.

  Journal of automated methods & management in chemistry 20080101

• Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India.

  Journal of the International AIDS Society 20080101

• Patch testing in non-immediate drug eruptions.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20080101

• [Dietary recommendations with practical examples of menus for people living with HIV/AIDS in sub-Saharan Africa].

  The Pan African medical journal 20080101

• Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.

  Bioorganic & medicinal chemistry letters 20071215

• Dosage adjustments in hepatic dysfunction.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215

• [HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].

  Zhonghua yi xue za zhi 20071211

• Susceptibility of Autographa californica multiple nucleopolyhedrovirus to inhibitors of DNA replication.

  Journal of virological methods 20071201

• Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.

  PLoS medicine 20071201

• Characterization of HIV-1 subtypes and viral antiretroviral drug resistance in men who have sex with men in Beijing, China.

  AIDS (London, England) 20071201

• Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.

  The Journal of infectious diseases 20071201

• Fatal Streptococcus equi subsp. ruminatorum infection in a man.

  Emerging infectious diseases 20071201

• Therapeutic options and challenges for substances of abuse.

  Dialogues in clinical neuroscience 20071201

• Screening for abacavir hypersensitivity.

  AIDS alert 20071201

• Review of tenofovir-emtricitabine.

  Therapeutics and clinical risk management 20071201

• Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

  AIDS (London, England) 20071130

• Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.

  AIDS (London, England) 20071130

• P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.

  Drug metabolism and disposition: the biological fate of chemicals 20071101

• Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071101

• HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China.

  Environmental health perspectives 20071101

• Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

  AIDS research and human retroviruses 20071101

• Management and therapy of chronic hepatitis C in HIV.

  Current opinion in HIV and AIDS 20071101

• Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.

  AIDS (London, England) 20071018

• A truvada hypersensitivity reaction simulating abacavir hypersensitivity.

  AIDS (London, England) 20071018

• Large lymphadenopathies complicating the abacavir hypersensitivity reaction.

  AIDS (London, England) 20071018

• Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

  Biomedical chromatography : BMC 20071001

• Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells.

  Antiviral research 20071001

• [Incidence and reasons of premature discontinuation of abacavir: results of a hospital investigation among 628 patients].

  Medecine et maladies infectieuses 20071001

• Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction.

  AIDS (London, England) 20071001

• HLA-B*5701 clinical testing: early experience in the United States.

  Pharmacogenetics and genomics 20071001

• Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Drug interactions involving ethanol and alcoholic beverages.

  Expert opinion on drug metabolism & toxicology 20071001

• Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20071001

• Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.

  The AIDS reader 20071001

• Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity.

  AIDS clinical care 20071001

• Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

  The Journal of biological chemistry 20070928

• Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

  AIDS (London, England) 20070912

• Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.

  AIDS (London, England) 20070912

• A comparison of three initial antiretroviral AIDS regimens.

  The New England journal of medicine 20070906

• Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.

  Antiviral research 20070901

• Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.

  The Journal of antimicrobial chemotherapy 20070901

• Modulation of heme and myristate binding to human serum albumin by anti-HIV drugs. An optical and NMR spectroscopic study.

  The FEBS journal 20070901

• Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?

  AIDS (London, England) 20070820

• Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070801

• Human leukocyte antigens and drug hypersensitivity.

  Current opinion in allergy and clinical immunology 20070801

• Drug hypersensitivity in HIV.

  Current opinion in allergy and clinical immunology 20070801

• Hair loss induced by lopinavir-ritonavir.

  Pharmacotherapy 20070801

• Translating pharmacogenomics: challenges on the road to the clinic.

  PLoS medicine 20070801

• The renaissance of fixed dose combinations: Combivir.

  Therapeutics and clinical risk management 20070801

• Review of tipranavir in the treatment of drug-resistant HIV.

  Therapeutics and clinical risk management 20070801

• Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.

  Drug metabolism and disposition: the biological fate of chemicals 20070701

• HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay.

  Tissue antigens 20070701

• Optimal timing and duration of induction therapy for HIV-1 infection.

  PLoS computational biology 20070701

• A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy.

  AIDS research and human retroviruses 20070701

• Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

  AIDS (London, England) 20070619

• Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan.

  The pharmacogenomics journal 20070601

• Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.

  Sexually transmitted infections 20070601

• A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601

• 'Personalized medicine: elusive dream or imminent reality?': A commentary.

  Clinical pharmacology and therapeutics 20070601

• Abacavir sulfate and mania in HIV.

  The American journal of psychiatry 20070601

• HPV oral infection. Case report of an HIV-positive Nigerian sex worker.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20070601

• FDA notifications. FDA grants approval for generic didanosine for oral solution.

  AIDS alert 20070601

• Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

  Biochemical pharmacology 20070515

• Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1.

  AIDS (London, England) 20070511

• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

  AIDS (London, England) 20070511

• Simultaneous determination of abacavir and zidovudine from rat tissues using HPLC with ultraviolet detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Advances in HIV therapeutics: the 14th CROI.

  The AIDS reader 20070501

• Drug hypersensitivity reactions in patients with HIV disease.

  Expert review of clinical immunology 20070501

• Syntheses and anti-HIV activities of (+/-)-norcarbovir and (+/-)-norabacavir.

  Organic & biomolecular chemistry 20070421

• Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).

  Journal of acquired immune deficiency syndromes (1999) 20070415

• Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

  The Journal of infectious diseases 20070415

• HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.

  The Journal of antimicrobial chemotherapy 20070401

• Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.

  AIDS patient care and STDs 20070401

• Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20070301

• Identification of abacavir hypersensitivity reaction in health care claims data.

  Pharmacoepidemiology and drug safety 20070301

• Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

  Pediatrics 20070301

• Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.

  Expert opinion on pharmacotherapy 20070301

• CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.

  The Annals of pharmacotherapy 20070301

• Evidence-based treatment for HIV-associated dementia and cognitive impairment: why so little?

  PLoS clinical trials 20070301

• Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial.

  PLoS clinical trials 20070301

• Abacavir modulates peroxynitrite-mediated oxidation of ferrous nitrosylated human serum heme-albumin.

  Biochemical and biophysical research communications 20070209

• Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.

  Journal of acquired immune deficiency syndromes (1999) 20070201

• Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

  The Journal of antimicrobial chemotherapy 20070201

• Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.

  AIDS (London, England) 20070130

• Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070101

• A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

  PLoS medicine 20070101

• Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.

  AIDS patient care and STDs 20070101

• Closing the access gap for health innovations: an open licensing proposal for universities.

  Globalization and health 20070101

• [A case of tuberculosis showing immune reconstitution syndrome after the initiation of antiretroviral therapy for HIV infection].

  Kekkaku : [Tuberculosis] 20070101

• Development and validation of a reverse-phase liquid chromatographic method for assay and related substances of abacavir sulfate.

  Journal of separation science 20070101

• Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations.

  Environmental and molecular mutagenesis 20070101

• HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?

  PloS one 20070101

• Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

  Retrovirology 20070101

• The NEFA study: results at three years.

  AIDS reviews 20070101

• Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.

  BMC infectious diseases 20070101

• Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.

  Journal of medical case reports 20070101

• Predictors of disease progression in HIV infection: a review.

  AIDS research and therapy 20070101

• AIDS in the Third World: how to stop the HIV infection?

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Anti-HIV drugs.

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts.

  AIDS research and therapy 20070101

• Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.

  BMC infectious diseases 20070101

• Antiretroviral treatment of HIV infection: Swedish recommendations 2007.

  Scandinavian journal of infectious diseases 20070101

• First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.

  Antiviral therapy 20070101

• Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

  Drugs 20070101

• Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients.

  HIV clinical trials 20070101

• Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.

  HIV clinical trials 20070101

• Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source.

  Virology journal 20070101

• Nucleoside and nucleotide reverse transcriptase inhibitors in children.

  Clinical drug investigation 20070101

• Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.

  Rapid communications in mass spectrometry : RCM 20070101

• Dermatologic adverse effects of antiretroviral therapy: recognition and management.

  American journal of clinical dermatology 20070101

• Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

  Orphanet journal of rare diseases 20070101

• Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.

  Antiviral therapy 20070101

• Update on the treatment of chronic hepatitis C in HIV-infected patients.

  AIDS reviews 20070101

• Differential drug resistance acquisition in HIV-1 of subtypes B and C.

  PloS one 20070101

• Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.

  Antiviral therapy 20070101

• Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

  Antiviral therapy 20070101

• Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings.

  PloS one 20070101

• Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.

  Retrovirology 20070101

• Complications and side effects. Abacavir hypersensitivity testing results--Montreal.

  TreatmentUpdate 20070101

• Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS.

  Retrovirology 20070101

• External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

  Antiviral therapy 20070101

• Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20070101

• Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania.

  BMC public health 20070101

• A new and short convergent synthetic strategy to carbocyclic nucleosides.

  Nucleosides, nucleotides & nucleic acids 20070101

• The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.

  Antiviral chemistry & chemotherapy 20070101

• [Pilot study of antiretroviral therapy in Djibouti].

  Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 20070101

• Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal.

  Journal of the International AIDS Society 20070101

• Maraviroc: the evidence for its potential in the management of HIV.

  Core evidence 20070101

• Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

  Antimicrobial agents and chemotherapy 20061201

• Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.

  The Pediatric infectious disease journal 20061201

• Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review.

  Medical science monitor : international medical journal of experimental and clinical research 20061201

• Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.

  Expert opinion on pharmacotherapy 20061201

• Overview of the pharmacoeconomics of pharmacogenetics.

  Pharmacogenomics 20061201

• Advisory issued for Epzicom.

  AIDS patient care and STDs 20061201

• FDA approves generic abacavir sulfate tablets.

  AIDS alert 20061201

• Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.

  Journal of acquired immune deficiency syndromes (1999) 20061101

• Hepatitis B in liver transplant recipients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20061101

• Metabolic abnormalities in HIV-infected patients: an update.

  Current infectious disease reports 20061101

• Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.

  PLoS medicine 20061101

• Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.

  AIDS clinical care 20061101

• A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

  AIDS (London, England) 20061024

• Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

  AIDS (London, England) 20061024

• Pharmacogenetics of HIV therapy.

  Pharmacogenetics and genomics 20061001

• Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better?

  The Lancet. Infectious diseases 20061001

• The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line.

  AIDS research and human retroviruses 20061001

• Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.

  The Journal of infectious diseases 20060901

• Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient.

  Optometry (St. Louis, Mo.) 20060901

• Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.

  AIDS patient care and STDs 20060901

• Management of antiretroviral drug toxicity.

  Current opinion in HIV and AIDS 20060901

• Examining the production costs of antiretroviral drugs.

  AIDS (London, England) 20060822

• Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

  JAMA 20060816

• The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

  Lancet (London, England) 20060805

• An update and review of antiretroviral therapy.

  Pharmacotherapy 20060801

• Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 20060801

• Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?

  The British journal of dermatology 20060801

• National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?

  AIDS (London, England) 20060713

• Human genetic variability and HIV treatment response.

  Current HIV/AIDS reports 20060701

• A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.

  The Journal of infectious diseases 20060701

• Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060701

• Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060701

• HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.

  HIV medicine 20060701

• Synthesis of carbovir and abacavir from a carbocyclic precursor.

  Current protocols in nucleic acid chemistry 20060701

• Investigating new antiretroviral combinations.

  The Journal of infectious diseases 20060615

• Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.

  Journal of medicinal chemistry 20060615

• HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

  AIDS (London, England) 20060612

• Abacavir hypersensitivity reaction in primary HIV infection.

  AIDS (London, England) 20060612

• Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060601

• Antiretroviral drug resistance and routine therapy, Cameroon.

  Emerging infectious diseases 20060601

• Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.

  The Pediatric infectious disease journal 20060601

• The clinical implications of antiretroviral pharmacogenomics.

  Pharmacogenomics 20060601

• Bioequivalence of abacavir generic and innovator formulations under fasting and fed conditions.

  International journal of clinical pharmacology and therapeutics 20060601

• [Antiretroviral treatment associated life-threatening adverse events].

  Medicina clinica 20060520

• Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.

  Journal of medical virology 20060501

• A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.

  Pharmacogenetics and genomics 20060501

• Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?

  International journal of clinical practice 20060501

• The pharmacogenetics of antiretroviral therapy.

  Current opinion in HIV and AIDS 20060501

• N6-methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates.

  Biochemical pharmacology 20060428

• Abacavir prodrugs: microwave-assisted synthesis and their evaluation of anti-HIV activities.

  Bioorganic & medicinal chemistry letters 20060415

• Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).

  Journal of acquired immune deficiency syndromes (1999) 20060415

• Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.

  The Pediatric infectious disease journal 20060401

• Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data.

  AIDS research and human retroviruses 20060401

• Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.

  Journal of medicinal chemistry 20060323

• Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.

  PLoS medicine 20060301

• Antiretroviral therapy and dyslipidaemia: unlocking the code.

  PLoS medicine 20060301

• Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.

  European journal of haematology 20060301

• Genetic factors in the predisposition to drug-induced hypersensitivity reactions.

  The AAPS journal 20060301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060301

• Immune mechanisms in drug allergy.

  Allergology international : official journal of the Japanese Society of Allergology 20060301

• Impact of pregnancy on abacavir pharmacokinetics.

  AIDS (London, England) 20060227

• Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.

  Journal of acquired immune deficiency syndromes (1999) 20060201

• In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

  Antimicrobial agents and chemotherapy 20060201

• Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses.

  Arzneimittel-Forschung 20060201

• Acute respiratory manifestations of the abacavir hypersensitivity reaction.

  AIDS (London, England) 20060109

• Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.

  Journal of medical virology 20060101

• Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.

  Pharmacogenomics 20060101

• The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.

  Cerebrospinal fluid research 20060101

• Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

  Nucleosides, nucleotides & nucleic acids 20060101

• An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.

  Antiviral therapy 20060101

• DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.

  BMC infectious diseases 20060101

• Assessing the effect of HAART on change in quality of life among HIV-infected women.

  AIDS research and therapy 20060101

• Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects.

  AIDS research and therapy 20060101

• The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.

  Antiviral therapy 20060101

• A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil.

  AIDS research and therapy 20060101

• Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome.

  HIV clinical trials 20060101

• Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy.

  BMC infectious diseases 20060101

• The impact of human genetic variation on HIV disease in the era of HAART.

  AIDS reviews 20060101

• Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors.

  HIV clinical trials 20060101

• Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania.

  BMC oral health 20060101

• Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.

  Radiation oncology (London, England) 20060101

• Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.

  Drug safety 20060101

• Genetic testing may avoid abacavir hypersensitivity reaction.

  AIDS treatment news 20060101

• Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.

  Journal of postgraduate medicine 20060101

• HIV research in Australia: linking basic research findings with clinical and public health outcomes.

  Retrovirology 20060101

• An immunological comparison of third companion in advanced drug-naive HIV-infected patients.

  HIV clinical trials 20060101

• Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.

  HIV clinical trials 20060101

• Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

  PloS one 20060101

• Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.

  HIV clinical trials 20060101

• Switching strategies to improve lipid profile and morphologic changes.

  AIDS reviews 20060101

• [Development and validation of laboratory methods for antiretroviral quantitation using HPLC].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.

  Antiviral therapy 20060101

• Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.

  Journal of the International AIDS Society 20060101

• Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215

• Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.

  The Journal of infectious diseases 20051201

• Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

  The Journal of infectious diseases 20051201

• Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).

  Journal of acquired immune deficiency syndromes (1999) 20051201

• Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.

  Expert review of anti-infective therapy 20051201

• Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin.

  The FEBS journal 20051201

• [Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].

  Annales de dermatologie et de venereologie 20051201

• Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

  Therapeutics and clinical risk management 20051201

• [Adverse effects of antiretroviral treatments].

  Presse medicale (Paris, France : 1983) 20051119

• A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.

  AIDS (London, England) 20051104

• Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.

  AIDS (London, England) 20051104

• Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.

  HIV medicine 20051101

• A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms.

  AIDS research and human retroviruses 20051101

• The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.

  The Journal of infectious diseases 20051015

• When do children convert from liquid antiretroviral to solid formulations?

  Pharmacy world & science : PWS 20051001

• Sequencing antiretroviral drugs for long-lasting suppression of HIV replication.

  The new microbiologica 20051001

• Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.

  AIDS (London, England) 20050902

• Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.

  Journal of acquired immune deficiency syndromes (1999) 20050815

• Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.

  Journal of acquired immune deficiency syndromes (1999) 20050801

• Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients.

  Journal of acquired immune deficiency syndromes (1999) 20050801

• Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.

  Journal of neurovirology 20050801

• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715

• [Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors].

  Medicina clinica 20050709

• KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.

  Antiviral research 20050701

• Fatal lactic acidosis associated with tenofovir and abacavir.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20050701

• Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050615

• Abacavir dosing with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050615

• Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.

  AIDS (London, England) 20050610

• Clinical and immunogenetic correlates of abacavir hypersensitivity.

  AIDS (London, England) 20050610

• [Consequences of replacing abacavir for indinavir in successful antiretroviral treatment of a patient with HIV infection].

  Presse medicale (Paris, France : 1983) 20050604

• Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.

  Mutation research 20050603

• Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.

  Antiviral research 20050601

• HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing.

  Tissue antigens 20050601

• A long-term survival case of small cell lung cancer in an HIV-infected patient.

  Japanese journal of clinical oncology 20050601

• Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.

  AIDS (London, England) 20050520

• Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.

  Journal of medicinal chemistry 20050519

• Therapeutic approaches to combating lipoatrophy: do they work?

  The Journal of antimicrobial chemotherapy 20050501

• Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase.

  Nature cell biology 20050501

• Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine.

  Antimicrobial agents and chemotherapy 20050501

• Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.

  The Journal of allergy and clinical immunology 20050501

• The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.

  HIV medicine 20050501

• Emerging anti-HIV drugs.

  Expert opinion on emerging drugs 20050501

• Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.

  Journal of acquired immune deficiency syndromes (1999) 20050415

• Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

  Journal of acquired immune deficiency syndromes (1999) 20050401

• Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.

  Journal of acquired immune deficiency syndromes (1999) 20050401

• [Toxic epidermal necrolysis associated with abacavir].

  Enfermedades infecciosas y microbiologia clinica 20050401

• Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

  PLoS medicine 20050401

• Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.

  AIDS (London, England) 20050325

• Abacavir pharmacokinetics in hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050315

• Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.

  Journal of clinical pharmacology 20050301

• Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050301

• In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

  Antimicrobial agents and chemotherapy 20050301

• Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.

  Journal of acquired immune deficiency syndromes (1999) 20050301

• Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.

  Journal of acquired immune deficiency syndromes (1999) 20050301

• Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

  AIDS patient care and STDs 20050301

• Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.

  HIV medicine 20050301

• Two-once-daily fixed-dose NRTI combinations for HIV.

  The Medical letter on drugs and therapeutics 20050227

• Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225

• Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

  AIDS (London, England) 20050218

• A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).

  The Journal of antimicrobial chemotherapy 20050201

• Interventions for managing antiretroviral therapy-associated lipoatrophy.

  Current opinion in infectious diseases 20050201

• Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

  Journal of acquired immune deficiency syndromes (1999) 20050201

• Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

  British journal of clinical pharmacology 20050201

• The impact of abacavir on lipids and lipodystrophy.

  The AIDS reader 20050201

• GlaxoSmithKline receives European approval for Kivexa.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20050201

• Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.

  AIDS (London, England) 20050103

• Lipoatrophy and mitochondrial DNA assays: see all, know all?

  AIDS (London, England) 20050103

• Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.

  Drugs 20050101

• Development and validation of a liquid chromatographic/tandem mass spectrometric assay for the quantitation of nucleoside HIV reverse transcriptase inhibitors in biological matrices.

  Journal of mass spectrometry : JMS 20050101

• Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

  BMC infectious diseases 20050101

• Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence.

  AIDS patient care and STDs 20050101

• Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.

  Lipids in health and disease 20050101

• Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.

  AIDS clinical care 20050101

• Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART).

  Revista do Instituto de Medicina Tropical de Sao Paulo 20050101

• Quadruple-drug induction HAART in advanced HIV infection.

  HIV clinical trials 20050101

• Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

  BMC infectious diseases 20050101

• Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

  Antiviral therapy 20050101

• In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.

  Antiviral therapy 20050101

• Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir.

  Clinical pharmacokinetics 20050101

• Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.

  Antiviral therapy 20050101

• Once-daily abacavir in place of twice-daily administration.

  The Annals of pharmacotherapy 20050101

• Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG).

  Journal of drugs in dermatology : JDD 20050101

• [An analisys fo causes for the discontinuation of a simplified antiretroviral regimen with abacavir, lamivudine and zidovudine].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20050101

• Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study.

  Antiviral therapy 20050101

• Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals.

  Antiviral therapy 20050101

• Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria.

  Antiviral therapy 20050101

• Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

  Antiviral therapy 20050101

• Will pharmacogenomic discoveries improve HIV therapeutics?

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101

• Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.

  BMC infectious diseases 20050101

• In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs.

  Antiviral chemistry & chemotherapy 20050101

• Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

  BMC infectious diseases 20050101

• The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS.

  Current pharmaceutical design 20050101

• Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?

  Antiviral therapy 20050101

• Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.

  Antiviral therapy 20050101

• Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

  Sexual health 20050101

• Scutellaria baicalensis decreases ritonavir-induced nausea.

  AIDS research and therapy 20050101

• Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.

  AIDS treatment news 20050101

• Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.

  HIV clinical trials 20050101

• Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.

  HIV clinical trials 20050101

• Anti-HIV agents. Abacavir once or twice daily.

  TreatmentUpdate 20050101

• Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions.

  Journal of immunotoxicology 20050101

• Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review.

  Journal of the International AIDS Society 20050101

• Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

  Journal of the International AIDS Society 20050101

• Genetic barriers to resistance and impact on clinical response.

  Journal of the International AIDS Society 20050101

• Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?

  Neurology 20041228

• More on abacavir-induced neuropsychiatric reactions.

  AIDS (London, England) 20041203

• Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function.

  Biomedical chromatography : BMC 20041201

• Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir.

  The Annals of pharmacotherapy 20041201

• Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

  PLoS medicine 20041201

• Short communication: benefits in the lipid profile after substitution of abacavir for Stavudine: a 48-week prospective study.

  AIDS research and human retroviruses 20041201

• No rechallenge for abacavir.

  AIDS patient care and STDs 20041201

• Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.

  Memorias do Instituto Oswaldo Cruz 20041201

• CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.

  AIDS (London, England) 20041105

• The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.

  AIDS (London, England) 20041105

• Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.

  AIDS (London, England) 20041105

• Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir.

  Biochemical pharmacology 20041101

• In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 20041101

• [Risk factors for Abacavir-induced hypersensibility syndrome in the 'real world'].

  Pathologie-biologie 20041101

• Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

  HIV medicine 20041101

• Tenofovir use in a patient with a severe renal impairment.

  HIV medicine 20041101

• HLA-B*5701 and abacavir hypersensitivity.

  Pharmacogenetics 20041101

• Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.

  Journal of virological methods 20041001

• Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.

  Journal of acquired immune deficiency syndromes (1999) 20041001

• Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20041001

• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

  PLoS medicine 20041001

• Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.

  Antiviral therapy 20041001

• Binding of anti-HIV drugs to human serum albumin.

  IUBMB life 20041001

• Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.

  AIDS (London, England) 20040903

• Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).

  The international journal of biochemistry & cell biology 20040901

• Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20040901

• New nucleoside/nucleotide backbone options: a review of recent studies.

  Journal of acquired immune deficiency syndromes (1999) 20040901

• Resistance issues with new nucleoside/nucleotide backbone options.

  Journal of acquired immune deficiency syndromes (1999) 20040901

• Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.

  Pharmacogenomics 20040901

• Sweet's syndrome following abacavir therapy.

  Journal of the American Academy of Dermatology 20040901

• Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5'-triphosphate metabolite levels.

  FEBS letters 20040827

• Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.

  AIDS (London, England) 20040820

• Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.

  The Journal of infectious diseases 20040815

• A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815

• Triple-nucleoside regimens versus efavirenz.

  The New England journal of medicine 20040812

• Triple-nucleoside regimens versus efavirenz.

  The New England journal of medicine 20040812

• FDA approves two combo brand-name AIDS drugs.

  Medicine & health (1997) 20040809

• Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.

  Journal of acquired immune deficiency syndromes (1999) 20040801

• HIV and drug allergy.

  Immunology and allergy clinics of North America 20040801

• Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.

  The Journal of antimicrobial chemotherapy 20040801

• SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

  AIDS (London, England) 20040723

• The pharmacogenetics of antiretroviral therapy: a review of studies to date.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040701

• Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.

  The Journal of clinical endocrinology and metabolism 20040701

• Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

  Current medical research and opinion 20040701

• Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.

  Current medical research and opinion 20040701

• Antiviral drugs in current clinical use.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601

• In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.

  Antiviral research 20040601

• Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20040601

• Bringing genomics to the bedside: a cost-effective pharmacogenomic test?

  Pharmacogenetics 20040601

• Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

  Pharmacogenetics 20040601

• [Cutaneous drug reactions: pharmacogenetic news].

  Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20040501

• Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

  AIDS (London, England) 20040430

• Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

  The New England journal of medicine 20040429

• [Valuable combination partner. Great benefit for therapy naive patients].

  MMW Fortschritte der Medizin 20040426

• Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.

  AIDS (London, England) 20040409

• Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors.

  Journal of neurovirology 20040401

• Abacavir hypersensitivity reaction predicted by genetic test.

  AIDS treatment news 20040326

• Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.

  Proceedings of the National Academy of Sciences of the United States of America 20040323

• Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.

  AIDS (London, England) 20040305

• GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.

  AIDS (London, England) 20040305

• [Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges].

  Praxis 20040303

• The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig.

  The Journal of pharmacology and experimental therapeutics 20040301

• Comment: Reasons for early abacavir discontinuation in HIV-infected patients.

  The Annals of pharmacotherapy 20040301

• Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.

  The Journal of antimicrobial chemotherapy 20040301

• Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301

• Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

  Pharmacogenomics 20040301

• Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.

  AIDS (London, England) 20040220

• Managing HIV lipoatrophy.

  Lancet (London, England) 20040207

• Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.

  Antiviral research 20040201

• Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.

  Hepatology (Baltimore, Md.) 20040201

• Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20040201

• Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

  Antiviral therapy 20040201

• Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.

  AIDS (London, England) 20040123

• Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040115

• Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

  Antimicrobial agents and chemotherapy 20040101

• The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20040101

• Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.

  Journal of acquired immune deficiency syndromes (1999) 20040101

• Determination of Abacavir in maternal plasma, amniotic fluid, fetal and placental tissues by a polarity switching liquid chromatography/tandem mass spectrometry method.

  Rapid communications in mass spectrometry : RCM 20040101

• Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs?

  Journal of neurovirology 20040101

• The reverse transcriptase (RT) mutation V118I is associated with virologic failure on abacavir-based antiretroviral treatment (ART) in HIV-1 infection.

  Scandinavian journal of infectious diseases 20040101

• Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients.

  HIV clinical trials 20040101

• Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.

  AIDS (London, England) 20040101

• EU issues warning about HAART regimen.

  AIDS patient care and STDs 20040101

• Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients.

  HIV clinical trials 20040101

• Interval estimation of genetic susceptibility for retrospective case-control studies.

  BMC genetics 20040101

• K65R, TAMs and tenofovir.

  AIDS reviews 20040101

• Triple nucleoside reverse transcriptase inhibitor therapy in children.

  Paediatric drugs 20040101

• Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.

  The Annals of pharmacotherapy 20040101

• Pharmacogenetics to predict drug-related adverse events.

  Toxicologic pathology 20040101

• K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.

  MedGenMed : Medscape general medicine 20040101

• Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20040101

• Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.

  Drugs 20040101

• Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.

  Clinical pharmacokinetics 20040101

• Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes).

  Theoretical biology & medical modelling 20040101

• Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).

  Psychosomatics 20040101

• Pharmacokinetics of antiretrovirals in pregnant women.

  Clinical pharmacokinetics 20040101

• New once-a-day drugs: Truvada and Epzicom.

  Positively aware : the monthly journal of the Test Positive Aware Network 20040101

• [Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20040101

• Treatment options for HIV, AIDS.

  FDA consumer 20040101

• Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.

  HIV clinical trials 20040101

• Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase.

  Biochemistry 20031223

• Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.

  Lancet (London, England) 20031213

• TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.

  AIDS (London, England) 20031205

• [Delayed drug sensitivity].

  Revista clinica espanola 20031201

• Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir.

  Pharmacology 20031201

• Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.

  The Journal of infectious diseases 20031201

• A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

  Antiviral therapy 20031201

• The continuing evolution of HIV therapy.

  The AIDS reader 20031201

• Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients.

  AIDS (London, England) 20031121

• Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.

  AIDS (London, England) 20031121

• Unusual clinical presentation of hypersensitivity reaction to abacavir.

  AIDS (London, England) 20031107

• Triple combinations regimens for HIV.

  The Lancet. Infectious diseases 20031101

• Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.

  Pharmacotherapy 20031101

• Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.

  The AIDS reader 20031101

• Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug.

  AIDS clinical care 20031101

• Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.

  AIDS clinical care 20031101

• Early nonresponse for tenofovir regimen.

  AIDS patient care and STDs 20031101

• [Hypersensitive reaction to abacavir or syphilitic hepatitis?].

  Presse medicale (Paris, France : 1983) 20031011

• Hydroxyurea transport across the blood-brain and blood-cerebrospinal fluid barriers of the guinea-pig.

  Journal of neurochemistry 20031001

• Tenofovir disoproxil fumarate.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031001

• Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031001

• Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

  The Journal of infectious diseases 20031001

• Reasons for early abacavir discontinuation in HIV-infected patients.

  The Annals of pharmacotherapy 20031001

• Epidemiological risk factors for hypersensitivity reactions to abacavir.

  HIV medicine 20031001

• Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20031001

• Warning issued on non-response rates.

  AIDS patient care and STDs 20031001

• The power of simplicity.

  International journal of STD & AIDS 20031001

• The reassurance of experience.

  International journal of STD & AIDS 20031001

• Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

  Antiviral therapy 20031001

• FTC (emtricitabine, Emtriva).

  Project Inform perspective 20031001

• Anti-HIV agents. Trying times for tenofovir and abacavir.

  TreatmentUpdate 20031001

• Anti-HIV agents. Abacavir--as good as AZT?

  TreatmentUpdate 20031001

• Anti-HIV agents. Abacavir only once-daily.

  TreatmentUpdate 20031001

• Anti-HIV agents. Who gets abacavir allergies?

  TreatmentUpdate 20031001

• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

  AIDS (London, England) 20030926

• Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

  The New England journal of medicine 20030911

• [Antiretroviral-induced toxiderma in HIV-infected patients].

  Presse medicale (Paris, France : 1983) 20030906

• Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the guinea pig brain barriers.

  The Journal of pharmacology and experimental therapeutics 20030901

• Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901

• GlaxoSmithKline halts AIDS study.

  The Lancet. Infectious diseases 20030901

• Perspectives on HAART: switch maintenance therapy.

  International journal of STD & AIDS 20030901

• Capillary electrophoresis-ion trap mass spectrometry analysis of Ziagen and its phosphorylated metabolites.

  Electrophoresis 20030901

• Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.

  AIDS clinical care 20030901

• Clinically relevant interpretation of genotype for resistance to abacavir.

  AIDS (London, England) 20030815

• Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• [Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone].

  Revista clinica espanola 20030801

• Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.

  The Journal of infectious diseases 20030801

• Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management.

  International journal of antimicrobial agents 20030801

• A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

  Antiviral therapy 20030801

• Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.

  Antiviral therapy 20030801

• Early intensification with abacavir in subjects at high risk for incomplete viral suppression.

  Antiviral therapy 20030801

• Failure of combination abacavir + tenofovir + lamivudine (3TC).

  AIDS treatment news 20030725

• Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

  The Journal of infectious diseases 20030715

• Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705

• Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030701

• Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction.

  International journal of STD & AIDS 20030701

• Cardiovascular pharmacogenetics in the SNP era.

  Journal of thrombosis and haemostasis : JTH 20030701

• AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701

• Abandon Trizivir when it's working well? A rebuttal.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701

• The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).

  Bioorganic & medicinal chemistry letters 20030616

• Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.

  The Journal of infectious diseases 20030615

• Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.

  Antimicrobial agents and chemotherapy 20030601

• Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601

• Cutaneous manifestations of antiviral therapy.

  Journal of the American Academy of Dermatology 20030601

• Comparison of nine resistance interpretation systems for HIV-1 genotyping.

  Antiviral therapy 20030601

• [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].

  Deutsche medizinische Wochenschrift (1946) 20030509

• A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

  Journal of virology 20030501

• A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.

  Journal of acquired immune deficiency syndromes (1999) 20030501

• Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20030501

• Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?

  Journal of HIV therapy 20030501

• Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system.

  Journal of HIV therapy 20030501

• Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.

  AIDS (London, England) 20030411

• Abacavir arm stopped in clinical trial.

  AIDS treatment news 20030404

• Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

  Antimicrobial agents and chemotherapy 20030401

• Antiretroviral therapy-induced psychosis: case report and brief review of the literature.

  HIV medicine 20030401

• HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

  Antiviral therapy 20030401

• Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.

  Antiviral therapy 20030401

• Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.

  Antiviral therapy 20030401

• K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

  Antiviral therapy 20030401

• Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20030301

• Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.

  AIDS (London, England) 20030214

• Mechanisms by which 2',3'-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy.

  Journal of neurochemistry 20030201

• Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

  Antiviral therapy 20030201

• Thymidine analogue-sparing highly active antiretroviral therapy (HAART).

  Journal of HIV therapy 20030201

• Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

  The Journal of infectious diseases 20030101

• Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.

  HIV medicine 20030101

• Sequencing to NRTI plus NNRTI-only combinations after virological failure of protease inhibitor-based combination HIV-1 therapy.

  HIV clinical trials 20030101

• Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.

  HIV clinical trials 20030101

• In vitro activity of potential anti-poxvirus agents.

  Antiviral research 20030101

• Variable virological outcomes according to the center providing antiretroviral therapy within the PharmAdapt clinical trial.

  HIV clinical trials 20030101

• Lamivudine/zidovudine/abacavir: triple combination tablet.

  Drugs 20030101

• HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

  Antiviral chemistry & chemotherapy 20030101

• Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

  BMC infectious diseases 20030101

• Hepatotoxicity of antiretroviral therapy.

  AIDS reviews 20030101

• 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002.

  Expert opinion on drug safety 20030101

• Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.

  HIV clinical trials 20030101

• Clinical vignette in antiretroviral therapy: rash illness.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20030101

• Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.

  Positively aware : the monthly journal of the Test Positive Aware Network 20030101

• Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection.

  Journal of intensive care medicine 20030101

• Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy.

  Scandinavian journal of infectious diseases. Supplementum 20030101

• Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.

  AIDS (London, England) 20021206

• Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

  Antiviral therapy 20021201

• Chronic cough induced by abacavir apart from a context of hypersensitivity.

  Allergie et immunologie 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes.

  Chemico-biological interactions 20021110

• Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.

  AIDS (London, England) 20021108

• New anti-HIV agents and targets.

  Medicinal research reviews 20021101

• The importance of being modest--reflections on the pharmacogenetics of abacavir.

  Pharmacogenomics 20021101

• Neuropsychiatric reaction induced by abacavir.

  The American journal of medicine 20021101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

  The Journal of biological chemistry 20021025

• The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

  AIDS (London, England) 20021018

• Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission.

  AIDS research and human retroviruses 20021010

• Stevens-Johnson syndrome associated with abacavir therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021001

• Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• The abacavir hypersensitivity reaction: a review.

  Clinical therapeutics 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.

  The Journal of infectious diseases 20020901

• The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• Disseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reaction.

  AIDS (London, England) 20020816

• Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.

  Clinical pharmacology and therapeutics 20020801

• FDA notifications. Product tampering labels Ziagen as Combivir.

  AIDS alert 20020801

• New developments in anti-HIV chemotherapy.

  Biochimica et biophysica acta 20020718

• Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

  JAMA 20020710

• Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

  JAMA 20020710

• Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

  AIDS (London, England) 20020705

• ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 20020701

• Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.

  Antiviral research 20020701

• Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy.

  The Journal of pediatrics 20020701

• Genome-based pharmacogenetics and the pharmaceutical industry.

  Nature reviews. Drug discovery 20020701

• Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains.

  HIV medicine 20020701

• Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug.

  AIDS (London, England) 20020614

• Gateways to Clinical Trials. June 2002.

  Methods and findings in experimental and clinical pharmacology 20020601

• Intracellular carbovir triphosphate levels in patients taking abacavir once a day.

  AIDS (London, England) 20020524

• Therapeutic vaccination in primary HIV infection, the Quest trial.

  Vaccine 20020506

• Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.

  AIDS (London, England) 20020503

• Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.

  AIDS (London, England) 20020503

• Trizivir.

  Expert opinion on pharmacotherapy 20020501

• A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.

  The Journal of infectious diseases 20020501

• Abacavir hypersensitivity reaction.

  AIDS patient care and STDs 20020501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020501

• HLA B57 and abacavir hypersensitivity.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20020501

• Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.

  Biochemistry 20020423

• Abacavir hypersensitivity reaction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020415

• Scientists find some genes a bad omen for anti-HIV drug.

  JAMA 20020403

• Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

  Antiviral research 20020401

• Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.

  The Journal of infectious diseases 20020401

• The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.

  HIV medicine 20020401

• Switch studies: a review.

  HIV medicine 20020401

• Risk factor analysis of hypersensitivity reactions to abacavir.

  Clinical therapeutics 20020401

• Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

  Lancet (London, England) 20020330

• Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.

  AIDS (London, England) 20020329

• Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.

  AIDS (London, England) 20020308

• [Mutations of resistance of HIV-1 in previously untreated patients at penitentiary centers of the Autonomous Community of Valencia, Spain. REPRICOVA study].

  Medicina clinica 20020302

• Individualising HIV treatment--pharmacogenetics and immunogenetics.

  Lancet (London, England) 20020302

• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  Lancet (London, England) 20020302

• Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.

  Lancet (London, England) 20020302

• Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

  Antimicrobial agents and chemotherapy 20020301

• Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent.

  Antimicrobial agents and chemotherapy 20020301

• Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.

  Antiviral therapy 20020301

• Switching to abacavir to reduce fat wasting.

  TreatmentUpdate 20020301

• Using abacavir to avoid lipid problems.

  TreatmentUpdate 20020301

• Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020215

• Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020215

• HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.

  AIDS (London, England) 20020215

• Role of sequencing in therapy selection.

  Journal of acquired immune deficiency syndromes (1999) 20020201

• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  The Lancet. Infectious diseases 20020201

• Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

  AIDS research and human retroviruses 20020120

• Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.

  Antiviral research 20020101

• Kawasaki-like syndrome: abacavir hypersensitivity?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020101

• Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.

  Journal of acquired immune deficiency syndromes (1999) 20020101

• Antiretroviral rounds. A very discordant response.

  AIDS clinical care 20020101

• Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens.

  HIV clinical trials 20020101

• Vertigo and abacavir.

  AIDS patient care and STDs 20020101

• Easier abacavir regimen has promising results.

  AIDS alert 20020101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020101

• 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.

  Positive living (Los Angeles, Calif.) 20020101

• Human immunodeficiency virus genotype and hypertriglyceridemia.

  Journal of clinical laboratory analysis 20020101

• Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

  Paediatric drugs 20020101

• The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.

  HIV clinical trials 20020101

• Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections.

  HIV clinical trials 20020101

• Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.

  AIDS reviews 20020101

• Management of protease inhibitor-associated hyperlipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.

  AIDS (London, England) 20011207

• Agranulocytosis and fever seven weeks after starting abacavir.

  AIDS (London, England) 20011207

• Understanding drug hypersensitivity: what to look for when prescribing abacavir.

  The AIDS reader 20011201

• Editorial comment: the challenge of prescribing abacavir.

  The AIDS reader 20011201

• Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.

  Proceedings of the National Academy of Sciences of the United States of America 20011120

• Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.

  The Journal of infectious diseases 20011115

• Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways.

  AIDS (London, England) 20011109

• Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

  The Journal of biological chemistry 20011102

• New developments in anti-HIV chemotherapy.

  Current medicinal chemistry 20011101

• The role of NNRTIs in antiretroviral combination therapy: an introduction.

  International journal of STD & AIDS 20011101

• Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.

  European journal of medical research 20011029

• High-performance liquid chromatographic assay for abacavir and its two major metabolites in human urine and cerebrospinal fluid.

  Journal of chromatography. B, Biomedical sciences and applications 20011025

• Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.

  Lancet (London, England) 20011020

• Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011015

• Comparing different triple-drug combinations.

  AIDS clinical care 20011001

• Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.

  Therapeutic drug monitoring 20011001

• Hypersensitivity related to abacavir in two members of a family.

  The Annals of pharmacotherapy 20011001

• Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

  Clinical therapeutics 20011001

• HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.

  AIDS (London, England) 20010928

• Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.

  The Journal of infectious diseases 20010915

• [Acceptance of antiretroviral therapy. HIV-infected patients assess convenient triple combination].

  MMW Fortschritte der Medizin 20010906

• Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.

  Antiviral research 20010901

• Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid.

  The Journal of pharmacology and experimental therapeutics 20010901

• Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.

  Nephron 20010901

• Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba.

  Revista panamericana de salud publica = Pan American journal of public health 20010901

• Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir.

  Antiviral chemistry & chemotherapy 20010901

• Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

  AIDS (London, England) 20010817

• Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.

  AIDS research and human retroviruses 20010810

• Antiviral drugs: current state of the art.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801

• Strategies for treating HIV-related lipodystrophy.

  Expert opinion on investigational drugs 20010801

• HIV and drug allergy.

  Current opinion in allergy and clinical immunology 20010801

• The abacavir hypersensitivity reaction and interruptions in therapy.

  AIDS (London, England) 20010706

• Resistance and cross-resistance to abacavir.

  HIV medicine 20010701

• Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.

  Antiviral therapy 20010601

• Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.

  Antiviral therapy 20010601

• Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.

  Antiviral therapy 20010601

• A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.

  Antiviral therapy 20010601

• Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010501

• Choosing which nuke to use first.

  The AIDS reader 20010501

• Drifting agenda for federal treatment research.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20010501

• Resistant to everything.

  AIDS clinical care 20010501

• Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Biomedical sciences and applications 20010425

• A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

  AIDS (London, England) 20010413

• [Observational study with abacavir. Decreased viral load and quality of life improves].

  MMW Fortschritte der Medizin 20010402

• [Determining resistance in HIV therapy. Careful interpretation only].

  MMW Fortschritte der Medizin 20010402

• Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.

  Journal of virology 20010401

• An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

  Controlled clinical trials 20010401

• A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.

  Pharmacotherapy 20010401

• Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20010401

• A near-fatal hypersensitivity reaction to abacavir: case report and literature review.

  The AIDS reader 20010401

• Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.

  AIDS (London, England) 20010330

• Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

  JAMA 20010307

• Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.

  The Journal of infectious diseases 20010301

• International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.

  Journal of acquired immune deficiency syndromes (1999) 20010301

• Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.

  Journal of clinical pharmacology 20010301

• Phase III trials for new PI.

  AIDS patient care and STDs 20010301

• Differential susceptibility of retroviruses to nucleoside analogues.

  Antiviral chemistry & chemotherapy 20010301

• Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

  The Journal of infectious diseases 20010215

• Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.

  AIDS (London, England) 20010126

• Abacavir and diabetes.

  The New England journal of medicine 20010111

• Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection.

  Journal of chromatography. B, Biomedical sciences and applications 20010105

• A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

  Pediatrics 20010101

• Trizivir on the market.

  Trends in microbiology 20010101

• Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20010101

• Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.

  Pharmacotherapy 20010101

• Triple-drug tablet approved for HIV infection.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101

• New developments in anti-HIV chemotherapy.

  Farmaco (Societa chimica italiana : 1989) 20010101

• Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

  Nucleosides, nucleotides & nucleic acids 20010101

• Triple nuke therapy--results after one year.

  TreatmentUpdate 20010101

• Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.

  Journal of human virology 20010101

• Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.

  Antiviral therapy 20010101

• Abacavir sulfate, lamivudine, and zidovudine (Trizivir).

  The Journal of the Association of Nurses in AIDS Care : JANAC 20010101

• Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.

  HIV medicine 20010101

• Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20001215

• Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.

  Antimicrobial agents and chemotherapy 20000801

• Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.

  AIDS research and human retroviruses 20000410

• A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.

  Journal of acquired immune deficiency syndromes (1999) 19991001

• Hydroxyurea-induced neurotoxicity in HIV disease.

  AIDS (London, England) 19990820

• Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.

  Journal of acquired immune deficiency syndromes (1999) 19990815

• Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.

  The Journal of infectious diseases 19990101

• Four new antiretroviral medications will soon offer more options to HIV patients.

  Faculty notes (New Orleans, La.) 19980101

• 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

  Antimicrobial agents and chemotherapy 19970501

• Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.

  Antimicrobial agents and chemotherapy 19970501

• Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.

  Antimicrobial agents and chemotherapy 19970501